GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Total Operating Expense

XRTX (XORTX Therapeutics) Total Operating Expense : $4.44 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Total Operating Expense?

XORTX Therapeutics's Total Operating Expense for the three months ended in Sep. 2024 was $0.88 Mil. XORTX Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was $4.44 Mil.

XORTX Therapeutics Total Operating Expense Historical Data

The historical data trend for XORTX Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Total Operating Expense Chart

XORTX Therapeutics Annual Data
Trend Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only 0.43 1.02 2.91 10.29 6.05

XORTX Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.39 0.98 1.09 1.49 0.88

XORTX Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XORTX Therapeutics Total Operating Expense Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Total Operating Expense
Comparable Companies
XCNQ:BETR XCNQ:DRUG XCNQ:CHGX XCNQ:TRYP TSXV:HEM TSXV:RKV TSXV:KNE TSXV:RP NEOE:AWKN TSX:AEZS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ANUA:Germany XRTX:Canada
Address
3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
Website
https://www.xortx.com
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.